| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Am I a scientist?
|
Kerep, Ana Zelić
|
|
|
10 |
11 |
p. e878
|
artikel
|
| 2 |
Challenges facing women and girls with bleeding disorders
|
Doherty, Dearbhla
|
|
|
10 |
11 |
p. e875-e876
|
artikel
|
| 3 |
Clive Smith: pushing sporting boundaries
|
Smith, Clive
|
|
|
10 |
11 |
p. e877
|
artikel
|
| 4 |
Comparison of international guideline recommendations for the diagnosis of pulmonary embolism
|
Falster, Casper
|
|
|
10 |
11 |
p. e922-e935
|
artikel
|
| 5 |
Correction to Lancet Haematol 2023; 10: e333–45
|
|
|
|
10 |
11 |
p. e874
|
artikel
|
| 6 |
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
|
Pabst, Thomas
|
|
|
10 |
11 |
p. e902-e912
|
artikel
|
| 7 |
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
|
Lübbert, Michael
|
|
|
10 |
11 |
p. e879-e889
|
artikel
|
| 8 |
Decitabine versus intensive chemotherapy induction for older patients with acute myeloid leukaemia: a futile but successful trial
|
Montesinos, Pau
|
|
|
10 |
11 |
p. e866-e867
|
artikel
|
| 9 |
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study
|
Tiede, Andreas
|
|
|
10 |
11 |
p. e913-e921
|
artikel
|
| 10 |
Empowering patients with venous thromboembolism
|
The Lancet Haematology,
|
|
|
10 |
11 |
p. e865
|
artikel
|
| 11 |
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
|
Costa, Luciano J
|
|
|
10 |
11 |
p. e890-e901
|
artikel
|
| 12 |
MRD-guided treatment cessation in multiple myeloma
|
Derman, Benjamin A
|
|
|
10 |
11 |
p. e867-e868
|
artikel
|
| 13 |
Non-haematological grade 1 and 2 adverse events of frontline CPX-351 in patients with myelodysplastic syndromes
|
Sasaki, Koji
|
|
|
10 |
11 |
p. e872
|
artikel
|
| 14 |
Non-haematological grade 1 and 2 adverse events of frontline CPX-351 in patients with myelodysplastic syndromes – Authors' reply
|
Peterlin, Pierre
|
|
|
10 |
11 |
p. e872-e873
|
artikel
|
| 15 |
Rapidly loading emicizumab without immunosuppression in acquired haemophilia
|
Ragni, Margaret V
|
|
|
10 |
11 |
p. e870-e871
|
artikel
|
| 16 |
Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies
|
Chakraborty, Rajshekhar
|
|
|
10 |
11 |
p. e936-e940
|
artikel
|
| 17 |
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment
|
Fathi, Amir T
|
|
|
10 |
11 |
p. e868-e870
|
artikel
|
Tijdschrift beschrijving